Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 61.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 530,513 shares of the company’s stock after selling 844,009 shares during the quarter. Assenagon Asset Management S.A. owned 0.68% of Travere Therapeutics worth $9,242,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of TVTX. CWM LLC increased its position in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares in the last quarter. DRW Securities LLC purchased a new position in Travere Therapeutics during the 2nd quarter valued at about $95,000. Quarry LP purchased a new position in Travere Therapeutics during the 3rd quarter valued at about $105,000. Forefront Analytics LLC raised its position in Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after acquiring an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Travere Therapeutics in the second quarter valued at about $117,000.

Insider Transactions at Travere Therapeutics

In related news, CAO Sandra Calvin sold 12,090 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at $1,005,164.10. This trade represents a 18.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the sale, the insider now owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. The trade was a 3.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,596 shares of company stock valued at $527,262. Insiders own 4.06% of the company’s stock.

Travere Therapeutics Price Performance

TVTX stock opened at $18.37 on Friday. The firm has a market cap of $1.43 billion, a P/E ratio of -4.04 and a beta of 0.70. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.33. The stock has a 50-day simple moving average of $18.21 and a 200-day simple moving average of $14.51.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The company had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. During the same period last year, the firm earned ($1.17) earnings per share. The company’s revenue was up 69.6% on a year-over-year basis. On average, equities analysts predict that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on TVTX. Guggenheim lifted their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group reduced their price objective on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. Barclays lifted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating on the stock. Finally, Citigroup lowered their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a report on Friday, September 27th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.